Ventricular arrhythmia in chronic heart failure (CHF) is considered to be associated with stimulation of β -adrenergic receptors (β -ARs). Three classes of β -ARs have been identified; importantly, distinct from β 1 and β 2 subtypes, β 3-AR could inhibit arrhythmia. Intracellular Ca 2+ is considered as a predominant effecter of arrhythmia during heart failure. However, the exact role of β 3-AR in arrhythmia and Ca 2+ regulation in CHF is not clear yet. Therefore, we studied the effect of BRL37344, a specific β 3-AR activator, on CHF-related ventricular arrhythmia and cellular Ca 2+ transport. Rabbits with CHF induced by combined aortic insufficiency and aortic constriction were treated with BRL37344 in the presence or absence of β 1-AR and β 2-AR stimulation. We then evaluated the current produced by sodium calcium exchanger (I NCX ), an electrical marker of abnormal Ca 2+ removal through ion transporter protein sodium calcium exchanger (NCX), Ca 2+ transient, a sign of Ca 2+ entering the cell, concentration of Ca 2+ in sarcoplasmic reticulum (SR) (SR Ca 2+ load) and its abnormal release (SR Ca 2+ leak). After treatment with BRL37344, the incidence of ventricular arrhythmias induced by infusion of a β 1-AR or β 2-AR activator decreased significantly. Similarly, β 3-AR stimulation remarkably inhibited increase of I NCX , Ca 2+ transient, SR Ca 2+ load and leak induced by activation of β 1-AR or β 2-AR. SR59230A, a specific β 3-AR blocker, abolished the inhibitory effects of BRL37344. These results suggest that β 3-AR activation could inhibit ventricular arrhythmia through regulating intracellular Ca 2+ . Thus, β 3-AR is a feasible therapeutic target that holds promise in the treatment of ventricular arrhythmias in CHF.
Keywords: beta3-adrenergic receptor; ventricular arrhythmia; chronic heart failure; calcium handling; rabbit Tohoku J. Exp. Med., 2010, 222 (3), 167-174. © 2010 Tohoku University Medical Press Ventricular tachycardia (VT) is the most common arrhythmia in chronic heart failure (CHF) and primarily associated with sudden cardiac death (Kjekshus 1990 ). Thus, researches for exploring the mechanisms of ventricular tachycardia would have a significant impact on patients with CHF. As is known, Ca 2+ has been shown to affect the physiological and pathophysiological situation of the heart (Dhalla et al. 1982) . Calcium handling, a term defines as entire process of Ca 2+ entry, store, release and reuptake, is central to the control of heart rhythm and contraction (Gwathmey et al. 1987) . Thus, it is not surprising that abnormalities in calcium handling have been involved as key elements in many forms of heart disease like VT. A recent study also suggested that irregular calcium handling may induce VT in canines with tachycardia-induced CHF (Hoeker et al. 2009) . Ca 2+ transport is governed by the"Ca 2+ container" inside heart cells, called sarcoplasmic reticulum (SR) (Levine and Loewen 2006) . During progression of CHF, excessive activation of β -adrenergic receptors (β -ARs) and their downstream signaling pathways could impair the normal process of Ca 2+ moving in SR (Baartscheer et al. 2003 ). This will cause Ca 2+ overload in SR, thereby leading to abnormal Ca 2+ release called SR Ca 2+ leak. This abnormal Ca 2+ release from SR plays a major role in abnormal electrical activity of the heart (Yao et al. 1998) .
Generally, Ca 2+ is removed from cells mainly through L-type Ca 2+ channel (Yamakage and Namiki 2002 exchanger, NCX) (Carafoli et al. 2001 ). The NCX is considered one of the most important cellular mechanisms for removing Ca 2+ . A recent study demonstrated that the current produced by NCX (I NCX ), an electrical marker of abnormal Ca 2+ removal, represents the activity of NCX (Wongcharoen et al. 2006) . There are several factors that can influence the activity of NCX. In recent years, activa-tion of β -ARs has been implicated as a major factor that improves the activity of NCX (Reppel et al. 2007 ).
Up to now, three classes of β -ARs have been identified in the human heart (Strosberg 1995) . Activation of β 1-AR and β 2-AR results in increase in cardiac output and heart rate (Lefkowitz et al. 2000) . In contrast to the former subtypes, β 3-AR causes a decrease in force of contraction (Gauthier et al. 1998) . In addition to the contractility, β 3-AR stimulation has been shown to exhibit opposite effect on the electrical properties of the heart. For example, the ionic current such as L-type Ca 2+ current is reduced with β 3-AR stimulation (Cheng et al. 2001) . Interestingly, β 3-AR expression level was increased, while the levels of other subtypes were decreased in failing human heart, suggesting that compared with former subtypes, β 3-AR plays an absolute different role in CHF (Moniotte et al. 2001) . Recently, an inhibitory effect of β 3-AR on arrhythmia was reported; namely, β 3-AR stimulation was associated with the reduction of arrhythmias in canine VT model (Zhou et al. 2008) . These findings indicate β 3-AR is a potential therapeutic target in the treatment of arrhythmia. However, pathophysiological role of β 3-AR in calcium handling and its influence on former subtypes in arrhythmia remain uncertain.
Therefore, the principal aim of the present study was to examine whether β 3-AR reduces the arrhythmia through modulation of calcium handling and its relationship with the other subtypes of β -ARs in arrhythmia.
Material and Methods

Animals
Studies were performed on healthy adult New Zealand White rabbits of either sex (2.5 to 3.2 kg, purchased from center of experimental animal in medical college of Wuhan university). All the procedures were carried out according to the routine animal-care guidelines. All experimental procedures com plied with the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals.
Induction of CHF
CHF was induced by combined aortic insufficiency (AI) and aortic constriction (AC). Induction of AI was performed by inserting a catheter via carotid artery and repeatedly pushing it through the aortic valve till pulse pressure increase at least 50%. After 2 weeks, AC was performed. Each week after AC, the severity of AI and cardiac function were reevaluated by echocardiography with color flow mapping. Left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) dimensions and ejection fraction (EF) were acquired. Only the rabbits' LVESD exceeded 1.40 cm and EF < 40% were selected to sacrifice as previously described (Pogwizd 1995) .
In vivo drug infusions
Conscious rabbits (N = 12, respectively) had an intravenous line established and the surface ECG and Holter (GE marquette mars system) were monitored. After a 3-minute baseline recording (which showed no ectopic beat in ECG), isoproterenol (1 µ g/kg/min i.v.) plus ICI 118,551 (0.2 mg/kg i.v. over 5 min) (β 1-AR selective stimulation) were infused and continuous recording of heart rhythm was performed. After the heart rate returned to baseline (about 5 min later), a specific β 3-AR activator, BRL37344 (1.5 µ g/kg/hr) was administrated by infusion pump for 30 min. After that, the β 1-AR stimulation was repeated. In β 2-AR selective stimulation group, the stimulation protocol was only replaced by a bolus injection of zinterol (2.5 µ g/kg i.v. over 5 seconds). A specific β 3-AR blocker, SR59230A (0.5 mg·kg -1 ) was administrated after BRL37344 infusion.
Myocytes isolation
Left ventricular myocytes were isolated with 0.4 mg/mL collagenase and 0.1 mg/mL protenase E by the method previously described (Bassani et al. 1994) . To block back flow across the incompetent aortic valve in HF rabbits, a balloon tipped catheter was inserted across the aortic valve and inflated in the LV outflow tract.
Electrophysiology
Solutions. I NCX was measured by the whole cell ruptured-patch technique (electrode resistance ranged from 1 to 2 M) with membrane capacitance measured at 5 mV voltage steps. It was measured by the protocol previously described (Hobai et al. 1997 ). The external solution contained (in mmol/L): NaCl 145, MgCl 2 1, HEPES 5, CaCl 2 2, CsCl 5, and glucose 10 (pH 7.4, adjusted with NaOH Protocol. A multi-Clamp 700B amplifier (Axon Instruments, Union City, CA, USA) was interfaced with a 12-bit A/D-D/A converter (Digidata 1200, Axon Instruments). PClamp software (PClamp 9.0, Axon Instruments) was used for data acquisition and analysis. Data were filtered by a 5-kHz low-pass filter and digitized at 5 kHz.
I NCX was studied using standard voltage ramp protocol. From a holding potential of -40 mV, a 100-ms step depolarization to +80 mV was followed by a descending voltage ramp (from +80 mV to -140 mV at 100 mV/s). The protocol was applied every 10 seconds. I NCX was measured as the Ni-sensitive current. were averaged from myocytes studied. Then the mean differences in cell dimensions, cell dynamics and fluorescence ratios of the CHF myocytes obtained from the animals after CHF. Student t tests were used to compare the means of 2 groups. A value of p < 0.05 was considered significant.
Ca
Results
Incidence of VT
According to the severity, we classified ventricular arrhythmia into 3 categories: single premature ventricular complex (PVC), coupled PVC, and sustained VT (more than 4 beats). At baseline, none of the rabbits exhibited any ventricular arrhythmias. After β 1-AR or β 2-AR stimulation, all failing rabbits developed paroxysmal episodes of VT (An example of sustained VT run is shown in Fig. 1A ) After β 3-AR treatment, the incidences of all kinds of ventricular arrhythmias from β 1-AR stimulated rabbits decreased significantly (Fig. 1B) . Single PVC was reduced from 73 to 35 beats ( p < 0.01). Consistently, number of coupled PVCs (31 vs. 15 beats, p < 0.01) and sustained VT (28 vs. 11 episodes, p < 0.01) were also markedly diminished. Similar effect was also observed in β 2-AR stimulated rabbits (Fig. 1C) . After infusion of BRL37344, single PVC was reduced from 89 to 51 beats ( p < 0.01). Identically, number of coupled PVCs (35 vs. 19 beats, p < 0.01) and sustained VT (25 vs. 7 episodes, p < 0.01) were dramatically decreased. However, β 3-AR activator did not change the duration of sustained VT (10.5 ± 6.2 s vs. 11.8 ± 7.6 s).
Inhibition of I NCX
Compared with the baseline, the outward (at +40 mV) (0.65 ± 0.05 vs. 1.20 + 0.17 pA/pF, P < 0.05, N = 10) and inward (at -110 mV) (1.43 ± 0.14 vs. 1.87 ± 0.20 pA/pF, P < 0.05, N = 10) I NCX were decreased significantly during administration of BRL37344 (Fig. 2B, C, D) . Compared with myocytes in basal state, selective β1-AR (Fig. 2E , F, G) and β 2-AR (Fig. 2H, I , J) stimulation markedly increased outward and inward I NCX . These elevations were markedly attenuated when treated with BRL37344. After exposure to BRL37344, significant decreases of outward (at +40 mV) (β 1-AR: 1.75 ± 0.26 vs. 3.97 ± 0.38 pA/pF, p < 0.05; β 2-AR: 2.28 ± 0.38 vs. 5.09 ± 0.58 pA/pF, p < 0.05) and inward (at -110 mV) (β 1-AR : 0.98 ± 0.07 vs. 2.45 ± 0.15 pA/pF, p < 0.05; β 2-AR : 0.64 ± 0.03 vs. 1.86 ± 0.32 pA/pF, p < 0.05) I NCX were observed (N = 10 for each group).
Modulation of intracellular Ca
2+ handling Fig. 3A and B show representative Ca 2+ transients from CHF myocytes during field stimulation at 1Hz in each group. The mean Ca 2+ transient amplitude was significantly reduced (β 1-AR: 35.0 ± 6.6%, p < 0.05, β 2-AR: 32.7 ± 5.8%, p < 0.05, N = 14, respectively) after treating with BRL37344. Figure 4A shows how SR Ca 2+ leak depends on diastolic SR Ca 2+ and SR loading protocol. Figure 4B shows representative caffeine-induced Ca 2+ transients in each group. As shown in Fig. 4C and D ]I = 2 mM) (β 1-AR: 15.2 ± 4.3%, p < 0.05, N = 12; β 2-AR: 21.8 ± 6.9%, p < 0.05, N = 12) and relatively higher [Ca 2+ ]i ([Ca 2+ ]I = 5 mM) (β 1-AR: 11.3 ± 2.3%, p < 0.05, N = 12; β 2-AR: 29.6 ± 4.2%, p < 0.05, N = 12). Similar to results in SR Ca 2+ load, after stimulation with BRL37344, the mean SR Ca 2+ leak became much smaller than those in untreated state (β 1-AR: 44.2 ± 9.4%, p < 0.01, N = 12; β 2-AR: 52.1 ± 9.9%, p < 0.01, N = 12) (Fig. 4E) .
SR Ca 2+ leak was determined by SR Ca 2+ loads. The load and SR Ca 2+ leak before and after exposure to BRL37344, respectively. mean SR Ca 2+ load and leak were diminished obviously after exposure to BRL37344; (F, G) The "load-leak" curves represent the SR leak/ load relationship respectively; It indicated that BRL37344 markedly decrease SR Ca leak/ load relationship shown in Fig. 4F and 4G respectively indicated that BRL37344 markedly depressed SR Ca 2+ leak while the SR Ca 2+ load increased.
Verification of the specificity of action of BRL37344 on β 3-AR To verify the specificity of action of BRL37344 on β 3-AR, SR59230A, a selective β 3-AR blocker, was employed. When rabbits were administrated with SR59230A, the change in heart rate and arrhythmia response to BRL37344 was nearly abolished (heart rate: 280 vs. 258 beats per minute; single PVC: 73 vs. 66 beats, S; coupled PVC: 31 vs. 34, sustained VT: 28 vs. 25 episodes). Similar response was also exhibited on cell (outward I NCX : 1.20 ± 0.17 vs. 1.09 ± 0.12 pA/pF; inward I NCX : 1.87 ± 0.20 vs. 1.77 ± 0.17pA/pF). These data implied that the effect of BRL37344 in present study should result from selective activation of β 3-AR.
Discussion
The principal findings of present study were that (1) pretreatment with BRL37344 inhibited the ventricular arrhythmia induced by β 1-and β 2-AR activation in rabbit with CHF. (2) load and SR Ca 2+ Leak were also attenuated by β 3-AR activation. Our data showed that relief of impaired calcium handling may be part of mechanism whereby inhibitory effect of β 3-AR stimulation on arrhythmia in the failing hearts.
In present study, we found that β 3-AR activation could suppress irregular heart rhythm, as evidenced by remarkable decrease in incidence of VT. These results implied the importance of β 3-AR stimulation in arrhythmia. Previous study had shown that compared with β 1-and β 2-AR, β 3-AR performs the opposite function in control of heart rate and contraction during end-stage heart failure (Moniotte et al. 2001) . Moreover, there is evidence suggesting that β 1-and β 2-AR stimulation are supposed to serve promotive role in arrhythmia (Zhou et al. 2004 ) and their blockade decreased the incidence of fatal VT. These results were consistent with our findings and implied β 3-AR plays an absolute different role in arrhythmia. That is, contrary to β 1-and β 2-AR, activation β 3-AR may contribute to attenuate incidence of arrhythmia.
In our study, we found a decrease in the incidence of VT after BRL37344 treatment, accompanied with the improvement of damaged calcium regulation. These outcomes indicate that inhibition of arrhythmia with BRL37344 may be explained by its prevention of impairment of intracellular Ca 2+ regulation. We have also shown that activation of β 1-AR or β 2-AR could make abnormal calcium handling become worse and β 3-AR stimulation could attenuate this change. These results suggest activation of β 3-AR acts as an intrinsic opponent of other subtypes. However, the mechanism for its repression of irregular Ca 2+ modulation induced by other β -ARs remains unknown. It is assumed that this effect may be explained by interaction of signaling cascade. Several lines of evidence indicate that a major signal from activation of β -ARs is mediated by protein kinase A (PKA), whose activity depends on the level of cyclic adenosine monophosphate (cAMP) (Lohse et al. 2003) . However, unlike the former subtypes, β 3-AR stimulation may increase another second messenger cyclic guanosine monophosphate (cGMP) (Senzaki et al. 2001) . The cGMP could interact with phosphodiesterase 2, an enzyme that degrades cAMP, thereby reducing cAMP level (Mongillo et al. 2006) . Thus, the activation of β 3-AR will lead to decrease of cAMP level and subsequently suppresses PKA cascades. Recently, Reppel and his colleagues (2007) showed a strong increase of I NCX upon stimulation by PKAdependent signaling pathways. Currie and Smith (1999) also showed that activation of PKA could promote SR Ca 2+ release. These results were in agreement with ours and implied that reserve of damaged Ca 2+ modulation by β 3-AR stimulation may through its inhibition on PKA signaling.
In this study, a selective β 3-AR activator BRL37344 was employed. However, it is a partial activator of the three types of β -ARs and has relative lower selectivity (Yanagisawa et al. 2000) . Therefore, to verify the specificity of action of BRL37344 on β 3-AR, we employed SR59230A, a specific β 3-AR inhibitor, thereby showing that the original inhibitory effects of BRL37344 were nearly abolished after administration of SR59230A. These data provide strong evidence that such repression induced by BRL37344 is resulted from selective activation of β 3-AR.
In summary, the present study has demonstrated that the activation of β 3-AR obviously ameliorates the susceptibility to ventricular arrhythmias through modulating calcium handling. Therefore, the β 3-AR may be a novel pharmacological target to current strategies for treatment of fatal VT in CHF.
